SEC Form 4 · accession 0000899243-18-008009
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Mar 19, 2018
Accepted (ET)
Mar 19, 2018 · 6:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 19, 2018 | C | 1,496,813 | — | A | 1,496,813 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Convertible Preferred StockF1 | — | Mar 19, 2018 | C | 1,496,813 | D | — | — | Common Stock | 1,496,813 | 0 | D |
Explanation of responses
- F1The Series C Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The Series C Convertible Preferred Stock reported in the table above reflects a 3.96-for-1 reverse stock split that was effected in connection with the Issuer's initial public offering. The shares had no expiration date.